title: Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses.
abstract: Herpes simplex virus type 1 (HSV-1) infects a wide range of cells, including dendritic cells. Consequently, HSV-1 vectors may be capable of eliciting strong immune responses to vectored antigens. To test this hypothesis, an HSV-1 amplicon plasmid encoding human immunodeficiency virus type 1 gp120 was constructed, and murine immune responses to helper virus-free amplicon preparations derived from this construct were evaluated. Initial studies revealed that a single intramuscular (i.m.) injection of 10(6) infectious units (i.u.) of HSV:gp120 amplicon particles (HSV:gp120) elicited Env-specific cellular and humoral immune responses. A potent, CD8(+)-T-cell-mediated response to an H-2D(d)-restricted peptide from gp120 (RGPGRAFVTI) was measured by a gamma interferon ELISPOT and was confirmed by standard cytotoxic-T-lymphocyte assays. Immunoglobulin G enzyme-linked immunosorbent assay analysis showed the induction of a strong, Env-specific antibody response. An i.m. or an intradermal administration of HSV:gp120 at the tail base elicited a more potent cellular immune response than did an intraperitoneal (i.p.) inoculation, although an i.p. introduction generated a stronger humoral response. The immune response to HSV:gp120 was durable, with robust cellular and humoral responses persisting at 171 days after a single 10(6)-i.u. inoculation. The immune response to HSV:gp120 was also found to be dose dependent: as few as 10(4) i.u. elicited a strong T-cell response. Finally, HSV:gp120 elicited significant Env-specific cellular immune responses even in animals that had been previously infected with wild-type HSV-1. Taken together, these data strongly support the use of helper-free HSV-1 amplicon particles as vaccine delivery vectors.
authors: Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York 14642, USA.
authors: Peter K
authors: PK
authors: Hocknell
authors: Rebecca D
authors: RD
authors: Wiley
authors: Xiuqing
authors: X
authors: Wang
authors: Thomas G
authors: TG
authors: Evans
authors: William J
authors: WJ
authors: Bowers
authors: Tomas
authors: T
authors: Hanke
authors: Howard J
authors: HJ
authors: Federoff
authors: Stephen
authors: S
authors: Dewhurst
mesh_terms: D000818:Animals; D000917:Antibody Formation; D002460:Cell Line; D004279:DNA, Viral; D003673:Defective Viruses / Q000235:genetics / Q000276:immunology*; D005260:Female; D015870:Gene Expression; D005822:Genetic Vectors / Q000235:genetics / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000235:genetics / Q000276:immunology*; D006378:Helper Viruses; D018259:Herpesvirus 1, Human / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D014771:Virion
chemical_list: D004279:DNA, Viral; D015699:HIV Envelope Protein gp120